Maurer Alexander, Schiesser Helen, Skawran Stephan, Gennari Antonio G, Dittli Manuel, Burger Irene A, Mader Cäcilia, Berger Christoph, Eberli Daniel, Huellner Martin W, Messerli Michael
BJR Open. 2022 Feb 1;4(1):20210084. doi: 10.1259/bjro.20210084. eCollection 2022.
To assess the frequency and intensity of [F]-prostate-specific membrane antigen (PSMA)-1007 axillary uptake in lymph nodes ipsilateral to COVID-19 vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) in patients with prostate cancer referred for oncological [F]-PSMA positron emission tomography (PET)/CT or PET/MR imaging.
126 patients undergoing [F]-PSMA PET/CT or PET/MR imaging were retrospectively included. [F]-PSMA activity (maximum standardized uptake value) of ipsilateral axillary lymph nodes was measured and compared with the non-vaccinated contralateral side and with a non-vaccinated negative control group. [F]-PSMA active lymph node metastases were measured to serve as quantitative reference.
There was a significant difference in maximum standardized uptake value in ipsilateral and compared to contralateral axillary lymph nodes in the vaccination group ( = 63, < 0.001) and no such difference in the non-vaccinated control group ( = 0.379). Vaccinated patients showed mildly increased axillary lymph node [F]-PSMA uptake as compared to non-vaccinated patients ( = 0.03). [F]-PSMA activity of of lymph node metastases was significantly higher ( < 0.001) compared to axillary lymph nodes of vaccinated patients.
Our data suggest mildly increased [F]-PSMA uptake after COVID-19 vaccination in ipsilateral axillary lymph nodes. However, given the significantly higher [F]-PSMA uptake of prostatic lymph node metastases compared to "reactive" nodes after COVID-19 vaccination, no therapeutic and diagnostic dilemma is to be expected.
No specific preparations or precautions ( adaption of vaccination scheduling) need to be undertaken in patients undergoing [F]-PSMA PET imaging after COVID-19 vaccination.
评估接受BNT162b2（辉瑞-生物科技公司）或mRNA-1273（莫德纳公司）新冠疫苗接种的前列腺癌患者，在接受肿瘤学[F] - 前列腺特异性膜抗原（PSMA）正电子发射断层扫描（PET）/CT或PET/MR成像时，同侧腋窝淋巴结中[F] - PSMA - 1007摄取的频率和强度。
回顾性纳入126例接受[F] - PSMA PET/CT或PET/MR成像的患者。测量同侧腋窝淋巴结的[F] - PSMA活性（最大标准化摄取值），并与未接种疫苗的对侧以及未接种疫苗的阴性对照组进行比较。测量[F] - PSMA活性的淋巴结转移灶作为定量参考。
接种疫苗组同侧腋窝淋巴结与对侧腋窝淋巴结的最大标准化摄取值存在显著差异（n = 63，P < 0.001），而未接种疫苗的对照组无此差异（P = 0.379）。与未接种疫苗的患者相比，接种疫苗的患者腋窝淋巴结[F] - PSMA摄取轻度增加（P = 0.03）。与接种疫苗患者的腋窝淋巴结相比，淋巴结转移灶的[F] - PSMA活性显著更高（P < 0.001）。
我们的数据表明，新冠疫苗接种后同侧腋窝淋巴结中[F] - PSMA摄取轻度增加。然而，鉴于新冠疫苗接种后前列腺淋巴结转移灶的[F] - PSMA摄取显著高于“反应性”淋巴结，预计不会出现治疗和诊断困境。
新冠疫苗接种后接受[F] - PSMA PET成像的患者无需进行特殊准备或预防措施（调整疫苗接种计划）。
Zotero 插件
